Sarah Volkman, DO
Geriatric Medicine · Evansville, INNPI 1124512520
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations.
Across 67 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$156
- Otsuka America Pharmaceutical, Inc.$145
- Novartis$141
- Sumitomo Pharma America, Inc.$124
- Pfizer$82
- Lundbeck LLC$82
- plus $480 from 16 others
What the payments were for
- Food & beverage$1,210100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 8 | $156 |
| Otsuka America Pharmaceutical, Inc. | 7 | $145 |
| Novartis | 8 | $141 |
| Sumitomo Pharma America, Inc. | 7 | $124 |
| Pfizer | 5 | $82 |
| Lundbeck LLC | 4 | $82 |
| Amgen | 4 | $70 |
| AbbVie | 3 | $61 |
| Novo Nordisk | 4 | $57 |
| Astellas Pharma US Inc | 2 | $36 |
| Merck | 2 | $35 |
| Lilly USA, LLC | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$1,210 in reported general payments places this provider in the 80th percentile of 70 geriatric medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 595 | $329,641 |
| MyrbetriqMirabegron | 192 | $111,983 |
| OzempicSemaglutide | 90 | $90,805 |
| JardianceEmpagliflozin | 201 | $90,177 |
| XareltoRivaroxaban | 163 | $86,725 |
| HumiraAdalimumab | 11 | $79,914 |
| JanuviaSitagliptin Phosphate | 127 | $73,298 |
| GemtesaVibegron | 125 | $62,866 |
| FarxigaDapagliflozin Propanediol | 103 | $61,997 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $57,421 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $37,870 |
| LinzessLinaclotide | 61 | $35,994 |
| RexultiBrexpiprazole | 37 | $32,139 |
| TrulicityDulaglutide | 24 | $32,116 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $28,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $82 | $329,641595 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Spiriva Respimat | $13 | $154,727317 claims |
| AbbVieHumira, Linzess, Namzaric | $61 | $128,542111 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy | $156 | $118,049209 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $111,983192 claims |
| Novo NordiskOzempic | $57 | $90,80590 claims |
| MerckJanuvia, Belsomra | $35 | $81,430145 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $124 | $62,866125 claims |
| AstraZenecaFarxiga | $15 | $61,997103 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $35 | $46,44239 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $145 | $32,13937 claims |
| NovartisEntresto | $141 | $10,07211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 70 geriatric medicine providers in Indiana.
Other geriatric medicine in Evansville
- Karl SashEvansville$26K
- della EvansEvansville$1K
- William HardestyEvansville$62
- Robert FicaloraEvansville$14
- Malaz BoustaniIndianapolis$188K
- Gregory SpanglerKokomo$31K
- Jodie HarperIndianapolis$27K
- Arnold del PilarMishawaka$25K
- Lauren DandurandMerrillville$11K
- Jack BartoszekMishawaka$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.